Drug Profile
VCH 286
Alternative Names: VCH-286Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ViroChem Pharma
- Developer Vertex Pharmaceuticals
- Class Antiretrovirals; Small molecules
- Mechanism of Action CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in HIV-infections in Canada (PO)
- 12 Mar 2009 ViroChem Pharma has been acquired and merged into Vertex Pharmaceuticals
- 12 Mar 2009 ViroChem Pharma has been acquired by Vertex Pharmaceuticals